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ﻦﻣ،ﺍﺮﻬﺷ٥١ﺖﻗﺮﻐﺘﺳﺍﻲﺘﻟﺍﺔﺒﻗﺍﺮﻤﻟﺍﺓﺮﺘﻓﻲﻓﻰﺿﺮﻤﻟﺍﺕﺎﻨﻴﻋﺖﻣﺪﺨﺘﺳﺍ
ﺔﻋﻮﻤﺠﻣ(٧٤٥٢)ﻝﺰﻋﻢﺗﻭ.ﺽﺍﺮﻣﻸﻟﺔﺒﺒﺴﻤﻟﺍﺎﻳﺮﻴﺘﻜﺒﻟﺍﻝﺰﻌﻟﻲﻤﻴﻠﻌﺗﻰﻔﺸﺘﺴﻣ
ﺪﺻﺮﻟﺔﻟﻭﺰﻌﻤﻟﺍﺔﻳﺮﻴﺘﻜﺒﻟﺍﺕﻻﻼﺴﻟﺍﺕﺮﺒﺘﺧﺍﻚﻟﺬﻛﻭ.ﺎﻋﻮﻧ٢١ﻰﻟﺇﻲﻤﺘﻨﺗﺔﻳﺮﻴﺘﻜﺑ
ﺎﻣﻭﺎﻘﻣﺔﻟﻭﺰﻌﻤﻟﺍﺎﻳﺮﻴﺘﻜﺒﻟﺍﻦﻣﺩﺪﻋﻥﺎﻛﻭ.ﺔﻳﻮﻴﺤﻟﺍﺕﺍﺩﺎﻀﻤﻟﺍﺾﻌﺒﻟﺎﻬﺘﻣﻭﺎﻘﻣ
(٪٧.٧)ﺔﺒﺴﻨﺑﺖﻧﺎﻛﺔﻣﻭﺎﻘﻣﻞﻗﺃﻭﺔﺗﻭﺎﻔﺘﻣﺐﺴﻨﺑﺔﻣﺪﺨﺘﺴﻤﻟﺍﺔﻳﻮﻴﺤﻟﺍﺕﺍﺩﺎﻀﻤﻠﻟ
ﺚﻟﺎﺜﻟﺍﻞﻴﺠﻟﺍﺕﺍﺩﺎﻀﻤﻟﺔﻣﻭﺎﻘﻤﻟﺍﺓﻮﻗﺖﺣﻭﺍﺮﺗﺪﻗﻭ.ﺔﻴﻧﻮﻟﻮﻘﻟﺍﺔﻴﻜﻳﺮﺷﻹﺍﺎﻳﺮﻴﺘﻜﺒﻟ
ﺕﺍﺩﺎﻀﻤﻟﺍﺔﻋﻮﻤﺠﻣﺕﺮﻬﻇﺃﻚﻟﺫﻊﻣﻭ.٪١٥-٣٤ﻦﻴﺑﻦﻳﺭﻮﺒﺳﻮﻟﺎﻔﻴﻜﻟﺍﻦﻣ
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Open access under CC BY-NC-ND licefor the isolation of pathogenic bacteria. Bacterial isolates
were isolated and identifies by standard biochemical
procedures. Antibiotic sensitivity test were conducted for
each isolates by Kirby-Bauer’s/disc diffusion method.
Extended spectrum beta lactamase (ESBL) producers
were determined by double disc diffusion synergy test
(DDST) and iodometric test.
2547 bacterial isolates were found belonging to 12 species
namely: Escherichia coli (954), Staphylococcus aureus
(661), Klebsiella pneumoniae (301), Enterococcus faecalis
(175), Pseudomonas aeruginosa (121), Acinetobacter sp.
(110), Citrobacter sp. (69), Klebsiella oxytoca (51),
Proteus vulgaris (43), Proteus mirabilis (31), Enter-
obacter sp. (27), Morganella sp. (4), in descending or-
der. The isolated bacterial strains were further tested
for monitoring resistance to cefepime ceftazidime,
cefotaxime, ceftriaxone (all 30 mg/disc) and cefoper-
azone (75 mg/disc) of the third generation cephalospo-
rins (3GCs). Numbers of resistant isolates were in
descending order: Proteus vulgaris (76.7%), Morganella
sp. (75.0%), Enterococcus faecalis (71.4%), Pseudo-
monas aeruginosa (68.6%), Proteus mirabilis (67.7%),
Klebsiella oxytoca (62.6%) and Citrobacter sp. (52.1%)
cefepime (30 mg/disc) and the rest other bacteria were
of lesser resistant values with the least percent value,
Escherichia coli (7.7%). Similarly, Citrobacter sp.
(91.3%) showed resistance to ceftazidime (30 mg/disc)
and 76.8% resistant to cefotaxime (30 mg/disc). Proteus
mirabilis showed the highest resistance over all other
isolates as 90.3% to ceftriaxone (30 mg/disc) and 80.6%
to cefoperazone (75 mg/disc). The resistance values to
the tested 3GC antibiotics ranged from 43 to 51%.nse.
Surveillance of ESBL producing bacteria in a hospital 275Conclusion: Antibiotics inhibiting b-lactamase produc-
tion were used with a blithesome control over 12 ESBL
bacteria. The 3GC antibiotic group was significantly
effective in controlling the GN bacterial strains in this
study.
Keywords: Extended-spectrum b-lactamase; Multidrug resis-
tance; Nosocomial infections; Third generation
cephalosporin
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Resistance of pathogenic bacteria to drugs/antibiotics has
now become increasingly commonplace,1 due to the versatility
of the microbial genetic system,2 in the stress situation of the
presence of control agent(s). Frequent reports of resistance to
the b-lactam group of antibiotics in Gram-negative (GN)
bacteria are due to the capability of the production of
extended spectrum beta-lactamases (ESBLs) that degrade the
b-lactam ring.3 Particularly, patients with old-age troubles
admitted to hospitals for one or the other ailment generally
are multi-morbid and have reduced immune-competence;
eventually, they are increasingly compromising to antibiotic
resistant bacteria. Indeed, the management of infection
from pathogenic bacteria is utterly difficult, because of the
observed multiple resistance to several groups of antibiotics
in Pseudomonas aeruginosa, Staphylococcus aureus and
Escherichia coli, for example recorded in surveillance in this
hospital.4e6 There are several armamentaria of drug
resistance acquired by bacteria by mutations and genetic
exchange mechanisms involving plasmids/transposons and
chromosome that cause alterations in cell membranes by the
target cell for prevention of the entry of the control agents
or development of substitute enzymes that are not targeted
by drugs or the release of drug degrading/inactivating
enzymes like, ESBLs. There is continual evolution of these
mechanisms in bacteria due to the selection pressure from
newer antibiotics/drugs, so that each emerging drug
resistant strain is the suitable strain for survival in vivo, since
the multidrug resistance invariably enhances the virulence of
a pathogen.1,4e6
The b-lactam group of antibiotics comprising penicillin
and its derivatives including broad spectrum cephalosporins
and monobactams are hydrolysed by ESBL producing bac-
terial strains. Sometimes, precipitated health episodes in
hospitals and communities due to GN bacteria, E. coli and
Klebsiella pneumoniae spearhead as enteropathogens, and E.
coli and Acinetobacter baumannii are known as uropath-
ogens, while S. aureus and Pseudomonas aeruginosa cause
suppurations.1,5,7 Slowly, strains of Klebsiella oxytoca,
Enterobacter sp., Pseudomonas aeruginosa and Citrobacter
sp. are becoming prominent to cause invasive enteric
infections in the children under-5, alike in the developed
and developing worlds because of multidrug resistance. The
third generation cephalosporins (3GCs) namely, cefotaxime,
ceftazidime, ceftriaxone, cefpodoxime and cefixime were
developed because of the production of ampicillin-hydrolysing b-lactamases carried by plasmids, TEM1, TEM2
and SHV1. In the last two decades, further detection of b-
lactamases in strains of K. pneumoniae and Serratia mar-
cescens were reported to hydrolyse extended spectrum
cephalosporins (ESCs) in Germany for the first time with
simultaneous emergence of similar species with b-lactamase
production by non-glucose fermenting GN bacilli such as,
Haemophilus influenza and Moraxella catarrhalis,8,9 which
was followed by quick reports on degradations of 3GCs
from USA.10 Moreover, about 150 types of ESBL bacterial
strains had been described to have a worldwide
distribution, a decade ago11 that clearly demonstrated that
b-lactam antibiotic resistance emerged in geographic zones,
where a particular antibiotic was used first.12,13 Further,
ESBL producing bacteria often show cross resistance to
other groups of antibiotics like, fluoroquinolones. Further,
the matter of utter clinical annoyance incidentally was the
close relationship between ciprofloxacin resistance and
ESBL production in antimicrobial stewardship
programme.14 Indeed, surveillance studies on a pathogen
or a group provide a mirror of infection dynamics of a
hospital/community. It has been known that ESBL
harbouring patients require longer hospital stay in wards
or intensive care units (ICUs), longer use of devices d
ventilation, catheterisation and a few more that are
inductive often for longer hospitalisation d all stemming
from, as well as leading to severity of an illness arising
from an infection episode and exposure to more and more
nosocomial infections, followed by the use of higher
generation of antibiotics,15e17 sometimes impassably
compelling a patient’s transfer to hospice.
As early as 2001, b-lactamases are classified to four
Ambler classes, C, A, B and D. The Ambler class A has only
one Bush group.18,19 The group Ambler class C with b-
lactamases, called as AMPc enzymes, is resistant to b-
lactamase inhibitors such as, ceftazidime/clavulanate
(CAC), cefoperazone/sulbactam (CFS), amoxyclav (AMC)
and piperacillin/tazobactam (PT), which are coded by
chromosomal genes. This group of enzymes was originally
present in GN bacteria (Enterobacteriaceae), Pseudomonas
aeruginosa, Citrobacter sp., K. pneumoniae, while was absent
in GP bacteria. GNs remain susceptible to cefepime (a
fourth generation cephalosporin, 4GC) and carbapenems.
The Ambler class A enzymes are plasmid mediated and
they are too inhibited by b-lactamase-inhibitors, clav-
ulanate, sulbactam and tazobactam, borne by TEM and
SHV enzymes. Originally found in Enterobacteriaceae,
these enzymes were discovered in Neisseria and Vibrio sp.
and were widely available in K. pneumoniae strains isolated
from different zones. It had been shown that a large
number of ESBL enzyme from different bacterial groups
have been recognised in this class, some of which were
carbenicillin and carbapenem resistant; this number would
be more than 150. And metallo-b-lactamase is with a
metallic ion such as, zinc belonging to the Group Amber
class B is capable of degrading carbapenems. The last class
D is a handful of unidentified enzymes of the previous
classes, C, A and B.18,19
This surveillance has arisen out of necessity in a hospital
set up, as ESBL producers create a vacuum in empiric ther-
apy. The latter is used for several life-threatening disease and
S. Rout et al.276morbidities such as, burns and urinary tract infection cases,
as it takes 3e4 days for a culture reports for the real guidance
of treatment. Indeed, ESBL producers have evolved so
much, so that the 4GCs are needed to control them. Our
school has reported the notorious shenanigan of a K. pneu-
moniae MBL strain to cause uncontrollable episode in our
neonatal section.5 This paper records surveillance of two
most common GP bacteria and 10 most common GN
bacteria insinuating into wards, cabins, ICUs and neonatal
ICU (NICU) in causing untoward infection, challenging
ultimately the clean state of indoor section of the hospital.
This study should guide clinicians in the final treatment as
well as in empiric therapy in saving patients of all age
groups. This work nevertheless, is of 5 quarters (15
months) gives the present status of a philanthropic
hospital, attended by patients from rural areas, urban
slums as well as from well heeled mass, in a resource
limited setting. This Indian epitome of notoriously
annoying, ill-famous cohort of 12 GP and GN multidrug
resistant (MDR) bacteria should strengthen the epidemio-
logical database and would help fixing facilitation of quality
improvement in hospital management, and for the reduction
in cost of hospitalisation, as well as in the reduction of
morbidity and mortality of patients. This cohort of 12 bac-
teria is linked to all sorts of health ailments. The pharmacy
world too is anticipated to be benefitted by this and similar
studies on subtle MDR pathogens all over, for finesse in
dovetailing suitable drugs of non-microbial origin even, as
antimicrobials.20 As each bacterium monitored here could
cause grievous health episodes independently, multiple
infections with 2e3 MDR bacteria might cause treatment
failures. Consequently, it would help prevent, a priory d
the use of some lowbrow antibiotic regimen, for the
desperate patients in quandary, dabbling with a MDR
infection that might prove as the terminal bacteremia.Figure 1: Proteus mirabilis producing ESBL in double disc synergy
test. A disc of augmentin is flanked by two discs of 3GC antibi-
otics, ceftazidime 30 and cefotaxime 30 mg, at a distance of 30 mm
apart on a on an MH agar plate.Materials and Methods
Bacterial isolation and biochemical identification
Detection of ESBL strains were conducted over a period of
15 months (February 2011eApril 2012) in Department of
Microbiology of the institute. Clinical samples were collected
for isolation of strains from patients attending outpatients
department (OPD, taken as community source), as well as
patients admitted into wards, cabins, ICU and NICU of the
hospital. Bacterial isolates were obtained from 10 clinical
samples, blood, bodyfluids, cerebrospinal fluid, pus, skin swab,
sputum, stool, throat swabs, tracheal aspirates, and urine.
All the collected specimens except those of urine were
inoculated onto MacConkey and blood agar plates; urine
samples were inoculated to cysteine lysine electrolyte defi-
cient agar (CLED) plates. Those inoculated plates were
incubated aerobically at 37 C for 24 h. On the other hand,
collected blood samples were incubated at 37 C for over-
night to check the growth of bacteria. After incubation, those
blood samples were inoculated on blood, chocolate and
MacConkey agar plates and kept in same incubator. These
blood samples were inoculated at second, fourth and seventh
days of collection. Bacteria were identified basing on colony
characters, Gram-staining, motility and biochemical test.7,21The following GP bacteria were obtained: Enterococcus
faecalis and S. aureus; GN bacteria were: Acinetobacter sp.,
Citrobacter sp., Enterobacter sp., E. coli, K. oxytoca, K.
pneumoniae, Morganella sp., Proteus mirabilis, Proteus
vulgaris and Pseudomonas aeruginosa.
Antibiotic susceptibility test
All bacterial strains including standard strains of Micro-
bial Type Culture Collections (MTCC), Chandigarh, of each
bacterium were subjected to antibiotic sensitivity tests by the
Kirby-Bauer’s method/disc diffusion method, using a 4 mm
thick MuellereHinton (MH) agar medium (HiMedia,
Mumbai). An aliquot of 0.1 ml 0.5 McFarland equivalents,
approximately from an exponentially growing culture of a
bacterium was spread on agar for the development of lawn of
a strain, at 37 C in a BOD incubator (Remi CIM-12S).
Further, on the lawn-agar of each plate, 8 high potency
antibiotic discs (HiMedia) of 18 prescribed antibiotics were
placed at equal distances from one another. Plates were
incubated for 18 h at 37 C and were examined for size of
zones of inhibition around each disc, following the standard
antibiotic susceptibility test chart of Clinical Laboratory
Standard Institute (CLSI) guidelines.21
Detection of ESBL by double disc synergy test
Double disc synergy test (DDST) was used for the
determination of ESBL producers in 10 GN bacteria
(Figure 1). In this test, synergy was determined between a
disc of augmentin (a combination of amoxicillin 20 and
clavulanic acid 10 mg) and two discs of third-generation
cephalosporin antibiotics, ceftazidime 30 and cefotaxime
30 mg, all placed at a distance of 30 mm apart on a lawn
culture of a test bacterium on a MH agar plate. The test
Table 1: Distribution of bacteria isolated from clinical samples collected from 4 different hospital sections over 15 months (from
February 2011 to April 2012), recorded on quarterly basis.
Period ICU & NICU Wards & cabins Nosocomial total OPD Grand total
Feb 2011eApr 2011 94 (3.6) 215 (8.4) 309 (12.13) 247 (9.6) 556 (21.8)
May 2011eJul 2011 101(3.9) 317(12.4) 418 (16.4) 251(9.8) 669 (26.2)
Aug 2011eOct 2011 95 (3.7) 251 (9.8) 346 (13.5) 262 (10.2) 608 (23.8)
Nov 2011eJan 2012 112 (4.3) 223 (8.7) 335 (13.1) 255 (10.01) 590 (23.1)
Feb 2012eApr 2012 32 (1.2) 47 (1.8) 79 (3.1) 45 (1.7) 124 (4.8)
Total isolates 434 1053 1487 1060 2547
Mean  SD 86.8  31.4 210.6  99.8 297.4  128.6 210.2  93.5 509.4  219.3
SD, standard deviation. ICU, intensive care unit; NICU, neonatal intensive care unit; OPD, outpatient department;N¼ 2547. Numbers in
parenthesis are percent values of occurrence.
Surveillance of ESBL producing bacteria in a hospital 277organism was considered to produce ESBL, if the zone size
around both test antibiotic discs increased towards the
augmentin disc. This increase occurred, because the clav-
ulanic acid present in the augmentin disc gets inactivated by
the ESBL enzyme, produced by the test organism.4Iodometric method
The b-lactamase enzyme hydrolyses the b-lactam moiety
of penicillin and derivatives; eventually violet colour of
starcheiodine mixture becomes colourless by reducing
iodine to iodide. In the iodometric tube method, benzyl
penicillin was dissolved in phosphate buffer, which was
adjusted to pH 6. An aliquot of 0.1 ml of the solution was
taken in a micro-titre plate. The solution was made cloudy
with 3e4 colonies of bacteria. After 30e60 min, an aliquot of
20 mL sterile 1% starcheiodine solution was added. If the
violet colour of iodine turned colourless in 5 min, the isolate
was considered b-lactamase positive.4Table 2: Density of ESBL producers in isolated bacteria from
clinical samples.a
Clinical samples Bacterial
isolates
ESBL-positives among
isolates
Urine 1351 (53) 971(38.1)
Pus 311 (12.2) 172 (6.7)
Body fluids 261 (10.2) 144 (5.6)
Sputum 162 (6.3) 99 (3.8)
Skin swab 141 (5.5) 89 (3.4)
Blood 98 (3.8) 49 (1.9)
Throat swab 59 (2.3) 46 (1.8)
Tracheal
aspiration
74 (2.9) 31 (1.2)
Stool 39 (1.5) 28 (1)
Cerebrospinal
fluid
51 (2) 26 (1)
Grand total 2547 (100) 1655 (64.9)
a Numbers in parenthesis indicate percent values of the grand
total number of 2547 isolates.Determination of MIC
ESBL positive MDR strains were further used for ascer-
taining MIC value of 3GC antibiotics (cefotaxime, ceftazi-
dime, ceftriaxone, cefpodoxime and cefexime). A standard
MTCC bacterial strain was taken as a negative control for
each bacterium. The MIC value of each antibiotic against
ESBL producers and non-producers were determined in a 96-
well micro-titre plate. Three to four colonies of a freshly
grown plate of each test strain were inoculated into 5 ml of
MH broth and were incubated at 37 C for 18 h. Aliquots of
100 mL ofMH broth were added to all wells to each of which,
aliquots of 20 mL of bacterial culture was added, followed by
the addition of an aliquot of 80 mL of 512 mg/ml of an anti-
biotic of the cephalosporin group was added to the second
well of the micro-titre plate. These solutions were serially
diluted in two fold dilutions till a final concentration of 0.
25 mg/ml in the last (twelfth) well was obtained. Finally, an
aliquot of 5 mL of 0.5% triphenyl tetrazolium chloride (TTC)
was added to each well and the plate was incubated at 37 C
for 18 h. A pink colouration due to TTC in a well indicated
bacterial growth and the absence of any colour was the bac-
terial growth inhibition. The first well of the micro-plate was
the control without any antibiotic solution. The MIC value
was noted at the well, where pink colour was not manifested.Results
In the surveillance from 4 different hospital sections over
15 months (from February 2011 to April 2012), clinical
samples from hospitalised patients (ICUs, NICU, wards and
cabins) as well as from patients attending OPD were used for
the isolation of clinical bacteria. It was found that the
number of isolated bacteria were 1487 from hospital sources,
and those were 1060 from OPD sources. The isolated bac-
teria were 434 in number in ICUs and NICU, whereas those
were 1053 in number from wards and cabins; thus the total
isolates in 15 months were 2547 (Table 1).
Maximum number of bacterial isolates were obtained from
urine samples and other clinical samples yielded numbers of
bacteria in decreasing trend, urine > pus > body
fluids > sputum > skin swab > blood > tracheal
aspirates> throat swabs> cerebrospinal fluid> stool. Each of
2547 isolates was tested for ESBL positivity, 1655 number of
isolates were positive (Table 2). Among 2547 isolates, the
bacteria were seen in the decreasing order of predominance:
E. coli (954) > S. aureus (661) > K. pneumoniae (301) > E.
faecalis (175)>Pseudomonas aeruginosa (121)>Acinetobacter
sp. (110) > Citrobacter sp. (69) > K. oxytoca (51) > Proteus
vulgaris (43) > Proteus mirabilis (31) > Enterobacter
sp. (27)>Morganella sp. (4).
Table 3: Percent resistance of isolated bacteria to antibiotics of
penicillin group.
Bacteria AMP (%) PT (%)
Acinetobacter sp. 31.8 29.0
Citrobacter sp. 30.4 39.1
Enterobacter sp. 92.5 77.7
E. faecalis 75.4 74.7
E. coli 20.7 24.2
K. oxytoca 50.9 39.0
K. pneumoniae 42.5 28.9
Morganella sp. 50.0 50.0
Proteus mirabilis 93.5 51.6
Proteus vulgaris 81.3 67.4
Pseudomonas aeruginosa 55.3 62.8
S. aureus 18.3 20.2
Mean  SD 53.6  26.7 47.1  20.1
SD, standard deviation. Antibiotics (mg/disc): AMP, ampicillin
10; PT, piperacillin/tazobactam 100/10.
S. Rout et al.278Two antibiotics ampicillin (10 mg/disc) and piperacillin/
tazobactam (100/10 mg/disc) were used in antibiotic sensi-
tivity tests. It was seen that more than 50% strains of Proteus
mirabilis, Enterobacter sp. Pseudomonas aeruginosa, Proteus
vulgaris, E. faecalis and K. oxytoca as well as,Morganella sp.
were resistant to these two antibiotics. The 10 GN and 2 GP
bacteria were more resistant to ampicillin than piperacillin/
tazobactam (Table 3). Isolated bacterial strains were further
used for monitoring resistance to five 3GC antibiotics.
Maximum numbers of resistant isolates were recorded for
Proteus vulgaris (76.7%), Morganella sp. (75.0%), E.
faecalis (71.4%), Pseudomonas aeruginosa (68.6%), Proteus
mirabilis (67.7%), K. oxytoca (62.6%) and Citrobacter sp.
(52.1%) cefepime 30 mg/disc, and the rest other bacteria
were of the least percent value, E. coli (7.7%) cefepime
30 mg/disc. Similarly, Citrobacter sp. was highly resistant to
ceftazidime (91.3%); Citrobacter sp. was 76.8% resistant to
cefotaxime 30 mg/disc; Proteus mirabilis was 90.3%
resistant, followed by the rest other bacteria to ceftriaxone
30 mg/disc; and finally Proteus mirabilis was 80.6%
resistant to cefoperazone 75 mg/disc, compared with restTable 4: Percent resistance of isolated bacteria to antibiotics of thir
Bacteria CFM (%) CAZ (%)
Acinetobacter sp. 33.6 50.9
Citrobacter sp. 52.1 91.3
Enterobacter sp. 18.5 55.5
E. faecalis 71.4 33.7
E. coli 7.7 33.9
K. oxytoca 62.6 29.4
K. pneumoniae 32.2 29.9
Morganella sp. 75.0 50.0
Proteus mirabilis 67.7 12.9
Proteus vulgaris 76.7 37.2
Pseudomonas aeruginosa 68.6 19.0
S. aureus 13.7 79.3
Mean  SD 48.34  25.7 43.60  23.3
SD, standard deviation. Antibiotics (mg/disc): CFM, cefepime 30; CA
cefoperazone 75.other bacteria. And the percent resistance values were
ranged 43e51% to 3GC antibiotics (Table 4).
Four antibiotics belonging to b-lactamase inhibitor group
were used against the isolated 12 ESBL producing bacteria.
Those were ceftazidime/clavulanate 30/10, cefoperazone/sul-
bactam 75/10, amoxyclav 21/10 and piperacillin/tazobactam
100/10 were differentially resistance to bacteria. Ceftazidime/
clavulanate was resistant to Proteus mirabilis (90.3%); cefo-
perazone/sulbactam was resistant to Proteus mirabilis
(67.7%), amoxyclav was resistant to K. oxytoca (88.2%) and
piperacillin/tazobactam was resistant to Morganella sp.
(75%), as maximum values (Table 5). The fluoroquinolone
resistance of isolated GN bacteria was recorded using 4
antibiotics, ofloxacin 5, norfloxacin 10, gatifloxacin 5 and
levofloxacin 5 mg/disc. It was seen that Proteus mirabilis was
resistant to ofloxacin (93.5%), norfloxacin (83.8%), and
gatifloxacin (77.4%), while K. oxytoca was resistant to
levofloxacin (66.6%); however, most bacteria were resistant
to these antibiotics at the least significant percent values for
isolates (Table 6). GN isolates were further tested for
aminoglycosides (amikacin, gentamicin and netilmicin).
Pseudomonas aeruginosa (80.1%) was resistant to amikacin,
K. oxytoca (82.3%) was resistant to gentamicin, and
Pseudomonas aeruginosa (67.6%) was resistant to netilmicin,
with cited maximum values (Table 7).
All GN isolates were further tested with five 3GC anti-
biotics cefotaxime, ceftazidime, ceftriaxone, cefpodoxime
and cefixime. It was seen that the MIC values of the most
antibiotics for 10 GN isolates were 8e256 mg/ml. It was
ascertained that most of the bacteria except K. pneumoniae
and Proteus mirabilis had MIC value at 128e256 mg/ml,
suggesting a higher degree of resistance to cefotaxime. Aci-
netobacter sp. and Proteus mirabilis had minimum MIC
value of resistance to ceftazidime, 32 mg/ml; the rest other
bacteria had 64e256 mg/ml as MIC values (Table 8). The
other 3 antibiotics had more susceptibility at 8 mg/ml, as
MIC values for ceftriaxone against Acinetobacter sp. and
Enterobacter sp. Further, a MIC value of 8 mg/ml
cefpodoxime against Enterobacter sp. and K. oxytoca were
recorded, while Citrobacter sp. had the MIC value of 8 mg/
ml cefixime. The average values of MIC prima facie
indicated that both cefotaxime and ceftazidime were mored generation cephalosporins.
CTX (%) CTR (%) CS (%)
57.2 42.7 53.6
76.8 71.0 79.7
59.2 29.6 22.3
38.8 50.8 38.8
32.9 12.6 8.8
31.1 47 60.7
32.5 23.9 24.5
75.0 75.0 75.0
58 90.3 80.6
32.5 67.4 72.0
66.9 76.8 57.0
52.3 14.6 22.2
51.14  17.1 50.18  26.1 49.63  25.4
Z, ceftazidime 30; CTX, cefotaxime 30; CTR, ceftriaxone 30; CS,
Table 5: Percentage of resistance of isolated bacteria to antibiotics of b-lactamase inhibitor group.
Bacteria CAC CFS AMC PT
Acinetobacter sp. 34.5 35.4 38.1 39
Citrobacter sp. 47.8 53.6 23.1 46.3
Enterobacter sp. 25.9 18.5 51.5 22.2
E. faecalis 53.1 44.5 29.7 26.2
E. coli 16.1 10.1 9.9 70.8
K. oxytoca 43.1 45.0 88.2 62.7
K. pneumoniae 32.5 29.56 76.4 30.8
Morganella sp. 75.0 50.0 75.0 75.0
Proteus mirabilis 90.3 67.7 83.8 31.9
Proteus vulgaris 79.0 53.4 74.4 74.4
Pseudomonas aeruginosa 28.0 33.8 30.5 32.8
S. aureus 56.8 29.3 18.4 20.2
Mean  SD 48.55  23.2 39.28  16.3 49.98  28.2 44.40  20.8
SD, standard deviation. Antibiotics (mg/disc): CAC, ceftazidime/clavulanic acid 30/10; CFS, cefoperazone/sulbactam 75/10; AMC,
amoxyclav 21/10; PT, piperacillin/tazobactam 100/10.
Table 6: Percentage of resistance of isolated Gram-negative bacteria to antibiotics of fluoroquinolone group.
Bacteria OF NX GAT LV
Acinetobacter sp. 29.0 3.6 19.0 15.4
Citrobacter sp. 42.0 34.7 21.7 26.0
Enterobacter sp. 55.5 62.9 4.4 40.7
E. coli 26.0 24.5 18.6 8.7
K. oxytoca 68.6 72.5 70.5 66.6
K. pneumoniae 30.2 28.5 62.1 30.5
Morganella sp. 50.0 50.0 e 50.0
Proteus mirabilis 93.5 83.8 77.4 35.4
Proteus vulgaris 20.9 34.8 30.2 6.9
Pseudomonas aeruginosa 44.6 e e e
Mean  SD 46.12  22.2 43.96  25.5 33.81  28.8 31.18  19.6
SD, Standard deviation. Antibiotics (mg/disc): OF, ofloxacin 5; NX, norfloxacin 10; GAT, gatifloxacin 5; LV, levofloxacin 5.
Surveillance of ESBL producing bacteria in a hospital 279resistant to GN bacteria and later 3 antibiotics were less
resistant. On the contrary, a KruskaleWallis H test
revealed that the calculated H value of 9.41 was far
below that the tabulated value of þ9.49 at degree ofTable 7: Percent resistance of isolated Gram-negative bacteria
to antibiotics of aminoglycoside group.
Bacteria AK GEN NET
Acinetobacter sp. 22.7 29.0 19.0
Citrobacter sp. 8.6 7.2 5.7
Enterobacter sp. 77.7 55.5 51.8
E. coli 67.8 51.0 49.7
K. oxytoca 66.6 82.3 56.8
K. pneumoniae 61.4 47.5 11.6
Morganella sp. 50.0 75.0 e
Proteus mirabilis 67.7 58.3 45.1
Proteus vulgaris 48.8 53.4 30.2
Pseudomonas
aeruginosa
80.1 62.8 67.6
Mean  SD 53.78  22.9 49.55  21.2 32.02  22.9
SD, standard deviation. Antibiotics (mg/disc): AK, amikacin;
GEN, gentamicin 10; NET, netilmicin 30; e, not used.freedom 4, at p-value ¼ 0.05, which suggested the
acceptance of null hypothesis.Discussion
It was seen in this surveillance that, wards and cabins of
the hospital contributed more numbers of pathogenic strains
compared with ICUs and NICU. Further, nosocomial total
isolates in each quarter were significantly higher than total
OPD isolates. Moreover, urine and pus samples contributed
significantly higher densities of ESBL positive strains. Most
GN isolates were multi-resistant to five 3GC antibiotics. The
KruskaleWallisH test led to the conclusion, all the five 3GC
antibiotics were equally effective in controlling the GN
bacterial strains in the study.
Antimicrobial stewardship programme usually uses
certain antibiotics both in empiric therapy and for the reg-
ular control of an ailment like, a urinary tract infection (UTI)
episode. When an alternate antibiotic is thought of to control
unbridled, notorious MDR strains of K. pneumoniae, A.
baumannii and E. coli, occurring in UTI patients causing
cystitis and urosepsis, tigecycline was considered as an
effective antibiotic for MDR and ESBL strains. But the
difficulty in the use of an alternate higher generation
Table 8: MIC value as mg/ml between the ESBL positive strains among isolated bacteria with third generation cephalosporins.
Bacteria Cefotaxime Ceftazidime Ceftriaxone Cefpodoxime Cefixime
Acinetobacter sp. 256 32 8 16 64
Citrobacter sp. 128 64 16 256 8
E. faecalis 256 128 256 256 128
E. coli 256 256 256 256 256
Enterobacter sp. 256 128 8 8 16
K. oxytoca 128 256 256 8 256
K. pneumoniae 64 256 256 16 256
Morganella sp. 128 128 32 32 16
Proteus mirabilis 64 32 64 256 64
Proteus vulgaris 256 256 64 64 32
Pseudomonas aeruginosa 128 256 256 256 64
S. aureus 256 256 256 64 256
Mean  SD 166.4  80.9 166.4  99.8 121.6  117.3 116.8  120.8 103.2  107.5
SD, standard deviation. KruskaleWallisH test revealed that the calculatedH value of9.41 was far below than the tabulated value of 9.49,
at degree of freedom 4, and at p-value is 0.05.
S. Rout et al.280antibiotic in place of tigecycline cause raised levels of side
effects in host.22 Another problem detected with K.
pneumoniae pathogenesis is its virulence due to capsular
material forms of thick bundles of fibrillious structure that
cover the bacterial cell surface that impede penetration of
drug in to bacterial cells.23 In addition, adherence of 4e5
somatic O-antigens to host cells by fimbrial/non-fimbrial
means serve as virulence factors; thus resistance of the bac-
terium to 3GCs have been explained.24 In the USA even,
100% of clinical samples of E. coli and K. pneumoniae were
susceptible to ertapenem (carbapenem) in 2007.25 Thus,
carbapenemase originated first in a developed country.
In Japan, the occurrence of ESBL producing bacteria had
been quite less compared with other countries, but in a sur-
veillance of 7-year period up to 2009, E. coli, K. pneumoniae
and Proteus vulgaris were quite predominance in Hakakata-
ku. Japanese strains mostly exhibited TEM, SHV and CTX-
M strains.26 Nevertheless, being resistant to almost all
generations of cephalosporins, Japanese E. coli strains were
susceptible to carbapenems. Further, those strains did not
have co-resistance to aminoglycosides, but were resistant to
fluoroquinolones.26
The most striking situation is that all these bacterial
strains have emerged with resistance to many commonly
used antibiotic groups, aminoglycosides, macrolides, fluo-
roquinolones and others, chloramphenicol and tetracy-
cline.27 In addition, S. aureus isolates were resistant to the
most b-lactams and the inhibitor group (ampicilline
sulbactam, amoxicillineclavulanic acid, ticarcilline
clavulanic acid, piperacillinetazobactam).27,28 Thus, S.
aureus isolates were MDR, rather a continually evolving
paradigmatic GP pathogen. Further, the GN, E. coli too
has an equally acquired clonal nexus group and multi-
resistance has come up to notorious standards. Surpris-
ingly, these two bacteria were original commensals of human
body, but widespread antibiotic uses have led to such a sit-
uation of hospital and public health pandemonium.29
Further, nosocomial infections are reported from ICUs,
because of the severity of infection by one or other pathogen
in patients with wounds. This situation causes spread of
several infectious bacteria at a time by cross-infections.
Frequently, device associated nosocomial infections havebeen reported from many hospitals due to human errors,
despite better cleanliness of general hospital environments.4
Moreover, community-acquired S. aureus infections were
also too often reported,30,31 wherein, poverty remains an
obvious determinant in developing countries, at least to
avoid a crowded life. Indeed, nosocomial/community
spread of infections could be attributed to the lack of
general awareness among public, an indurate attitude or
the lack of specific awareness among paramedical staff,
and at least to the plethora of physiological and genetic
survival mechanisms of MDR bacterial strains.
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